OakChart

Humacyte Inc

HUMAHealthcare·Biotechnology·USA·Micro·NASD·Nov 11 • 3:59 PM ET

0.5917+0.0017 (0.29%)
2026-11-12 02:48 CET
Market cap
163.90 USD m
Revenue, TTM
2.40 USD m
Net income, TTM
-94.76 USD m
Free cash flow, TTM
-88.58 USD m
EPS diluted, TTM
-0.43
P/E
-
Compare

Price

HUMA against its 20, 50 and 200-day averages
2050200beatmiss
0.501.001.5023.5M47.0MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26HUMAclose 0.5920-day 0.4550-day 0.49200-day 0.780.5952w high52w low

61.2% under the 52-week high of 1.53 on 4 Jun 2026. 52-week low 0.34 on 14 Oct 2026. Last 15 sessions, 62.6% high to low

Volume 0.99× normal · the line is the 50-bar volume average

Profile

HUMA
52-week range, 21% of the way up
0.341.52

Humacyte, Inc. engages in the business of developing and manufacturing off-the-shelf, universally implantable, bioengineered human tissues, advanced tissue constructs, and organ systems with the goal of improving the lives of patients and transforming the practice of medicine. The company was founded by Laura E. Niklason, Shannon Dahl, and Juliana L. Blum on October 13, 2004 and is headquartered in Durham, NC.

Employees184
IPODec 01, 2020
Beta2.61
ATR, 14d0.06
Rel volume0.99
Short float10.93%
Insider own7.55%
Inst own26.10%

Snapshot

6 groups

Valuation

Index-
Market Cap164.37M
Enterprise Value166.18M
Income-94.76M
Sales2.40M
Book/sh0.07
Cash/sh0.23
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees184
IPODec 01, 2020

Ratios

P/E-
Forward P/E-
PEG-
P/S68.49
P/B9.10
P/C2.54
P/FCF-
EV/EBITDA-
EV/Sales69.24
Quick Ratio3.11
Current Ratio3.34
Debt/Eq3.68
LT Debt/Eq3.65
Option/ShortYes / Yes

Earnings

EPS (ttm)-0.43
EPS next Y-0.23
EPS next Q-0.08
EPS this Y-41.15%
EPS next Y36.83%
EPS next 5Y17.50%
EPS past 3/5Y-30.53% 53.14%
Sales past 3/5Y- -
EPS Y/Y TTM-82.58%
Sales Y/Y TTM52.51%
EPS Q/Q49.46%
Sales Q/Q36.52%
EarningsNov 10 BMO
EPS/Sales Surpr.37.95% 34.20%

Ownership

Insider Own7.55%
Insider Trans0.12%
Inst Own26.10%
Inst Trans6.17%
ROA-87.31%
ROE-1423.62%
ROIC-112.90%
Gross Margin-623.02%
Oper. Margin-4602.92%
Profit Margin-3955.05%
SMA2032.93%
SMA5019.57%
SMA200-24.47%
Trades-

Technical

Shs Outstand277.80M
Shs Float256.83M
Short Float10.93%
Short Ratio4.09
Short Interest28.07M
52W High1.52 -61.20%
52W Low0.34 75.58%
Volatility14.45% 12.99%
ATR (14)0.06
RSI (14)64.91
Beta2.61
Rel Volume0.99
Avg Volume6.87M
Volume6,778,363

Performance

Perf Week31.49%
Perf Month64.86%
Perf Quarter7.58%
Perf Half Y-47.64%
Perf YTD-38.40%
Perf Year-53.77%
Perf 3Y-74.82%
Perf 5Y-93.96%
Perf 10Y-
Recom1.67
Target Price1.64
Prev Close0.59
Price0.59
Change %0.29%

Analyst ratings

latest 10 of 12
DateActionAnalystRating changeTargetImplied
Oct 07, 2026InitiatedBBarclaysEqual Weight$0.50-15.5%
Aug 27, 2025InitiatedBBarclaysOverweight$3.50+491.5%
May 14, 2025ResumedHH.C. WainwrightBuy$4+576.0%
Dec 20, 2024ReiteratedHH.C. WainwrightBuy$12 → $15+2,435.1%
Dec 11, 2023InitiatedHH.C. WainwrightBuy$6+914.0%
Aug 14, 2023UpgradePPiper SandlerUnderweight → Neutral$2.75 → $3.50+491.5%
Jun 22, 2023InitiatedCCantor FitzgeraldOverweight$6+914.0%
May 16, 2022DowngradePPiper SandlerOverweight → Underweight$10 → $4+576.0%
Oct 29, 2021InitiatedCCowenOutperform$17+2,773.1%
Sep 24, 2021InitiatedOOppenheimerOutperform$16+2,604.1%

Peers

Mkt cap
TickerCompanyMkt cap
VCELVericel Corp3.03B
MDXGMimedx Group Inc484.47M
CELUCelularity Inc24.37M
LCTXLineage Cell Therapeutics Inc280.72M
CLGNCollPlant Biotechnologies Ltd7.48M
BSEMBioStem Technologies Inc27.45M
PROKProKidney Corp341.68M
ICUSeaStar Medical Holding Corp10.21M
MESOMesoblast Ltd ADR1.78B
NVNOenVVeno Medical Corp4.53M

Insider trading

9 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Jones Keith AnthonyDirectorSep 14 '26Buy0.5610,0005,62050,000Sep 15 04:05 PM
Jones Keith AnthonyDirectorAug 20 '26Buy0.6910,0006,93040,000Aug 21 04:05 PM
Jones Keith AnthonyDirectorAug 17 '26Buy0.5930,00017,82030,000Aug 19 04:00 PM
Sebelius KathleenDirectorMay 19 '26Buy0.8856,81850,000148,025May 20 04:33 PM
Constantino Michael T.DirectorMay 18 '26Buy0.8911,0009,84043,950May 20 04:32 PM
Sander Dale A.CFO and Chief Corp. Dev. OffMay 18 '26Sale0.9045,88741,147267,213May 20 04:31 PM
Parikh Shamik JChief Medical OfficerMay 18 '26Sale0.9045,88741,147272,713May 20 04:30 PM
Sander Dale A.OfficerMay 18 '26Proposed Sale0.9045,88741,147May 18 04:09 PM
Parikh Shamik JOfficerMay 18 '26Proposed Sale0.9045,88741,147May 18 03:56 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IBBiShares Biotechnology ETFAUM: 11.36B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
VHTVanguard Health Care ETFAUM: 21.51B
PRFZInvesco RAFI US 1500 Small-Mid ETFAUM: 2.66B
BUSMEA Bridgeway Ultra-Small Company Market ETFAUM: 111.21M
IBBQInvesco Nasdaq Biotechnology ETFAUM: 130.27M
BIBProShares Ultra Nasdaq Biotechnology 2X SharesAUM: 107.35M

News

latest 14 of 100
  • Five Presentations, One Leading Innovation: Humacyte's Acellular Tissue Engineered Vessel Takes Center Stage at VEITH 2026 (GlobeNewswire)
  • Humacyte Beats As Symvess Sales More Than Double, But Dilution, Negative Gross Margin And Shrinking Cash Shadow The Inflection (Earnings Whispers) +29.61%
  • Humacyte Reports Third Quarter 2026 Results, Highlighted by More Than Doubling Symvess Revenue and Expanding Commercial Adoption (GlobeNewswire)
  • Humacyte Highlights First-in-Human Coronary Bypass Study at American Heart Association Scientific Sessions 2026 (GlobeNewswire)
  • Humacyte Innovative Research in Coronary Bypass and Vascular Regeneration to be Highlighted at American Heart Association Scientific Sessions 2026 (GlobeNewswire) +10.65%
  • Humacyte Heads Into Q3 Needing Proof Its Rebuilt Trauma Launch Works As Dialysis Filing Nears (Earnings Whispers)
  • Humacyte To Announce 2026 Third Quarter Financial Results and Provide Business Update on November 10, 2026 (GlobeNewswire)
  • Humacyte Strengthens Intellectual Property Portfolio with Issuance of New U.S. Patent Covering Symvess and Other Bioengineered Tissues (GlobeNewswire) +5.33%
  • Humacyte at ASN Kidney Week: Phase 3 Trial Built for Women Shows ATEV Advantage Over Fistula, Getting Patients Off Catheters Months Sooner (GlobeNewswire) +5.40%
  • Humacyte Provides Commercial Update and Highlights Rapid Acceleration of Symvess Adoption by Hospitals (GlobeNewswire) +24.12%
  • Humacyte Announces Phase 3 V012 Trial Results for ATEV in Women Requiring Hemodialysis Access Accepted for a Late-Breaking Session Presentation at ASN Kidney Week 2026 (GlobeNewswire)
  • Flutter upgraded, AppFolio downgraded: Wall Street's top analyst calls (The Fly)
  • Humacyte Expands Board Expertise with Appointment of Scott Coward and Paul Kuznik (GlobeNewswire)
  • Humacyte to Present at the H.C. Wainwright 28th Annual Global Investment Conference (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-10-0.060-0.097-0.0601.030.776
2026Q22026-08-12-0.160-0.113-0.1570.411.045
2026Q12026-05-13-0.090-0.116-0.0890.501.467
2025Q42026-03-27-0.130-0.132-0.1330.471.356
2025Q32025-11-12-0.110-0.151-0.1110.750.927
2025Q22025-08-11-0.240-0.162-0.2420.301.006
2025Q12025-05-130.280-0.1910.2790.520.766
2024Q42025-03-28-0.160-0.250-0.1650.000.007
2024Q32024-11-08-0.330-0.249-0.3280.000.007
2024Q22024-08-13-0.480-0.238-0.4760.000.005
2024Q12024-05-10-0.290-0.226-0.2950.000.004
2023Q42024-03-22-0.240-0.240-0.2420.000.056
2023Q32023-11-09-0.250-0.254-0.2510.000.076
2023Q22023-08-14-0.220-0.220-0.2200.000.076
2023Q12023-05-12-0.360-0.210-0.3580.000.165
2022Q42023-03-24-0.040-0.235-0.0360.010.246

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2020FY-3.030--11.4261.50-
2021FY-0.660-1.547-0.6621.301.22
2022FY-0.120-0.410-0.1161.571.77
2023FY-1.070-1.052-1.0710.000.05
2024FY-1.260-1.349-1.2550.000.00
2025FY-0.260-0.293-0.2602.042.73
2026FY--0.367--4.40
2027FY--0.232--23.54
2028FY--0.146--114.87
2029FY-0.040--220.31
2030FY-0.200--327.29

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-105302.512.003.37
2026Q4S2026-10-265011.840.703.37
2026Q4S2026-10-095041.840.703.37
2026Q4S2026-08-305131.840.703.37
2026Q4S2026-08-195141.840.703.37
2026Q4S2026-08-125051.840.703.37
2026Q4S2026-08-105032.420.933.70
2026Q4S2026-07-275022.571.003.70
2026Q4S2026-06-165042.571.003.70
2026Q4S2026-06-155032.731.004.14
2026Q4S2026-06-135032.731.004.14
2026Q4S2026-06-105132.731.004.14
2026Q4S2026-06-055142.731.004.14
2026Q4S2026-06-045142.731.004.14

Estimate history

EPS, annual-11.426-0.662-0.116-1.071-1.255-0.258-0.4349
Period202020212022202320242025TTM
EPS, quarterly-0.328-0.1650.279-0.242-0.111-0.133-0.089-0.157-0.056
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual000002.0382.4
Period202020212022202320242025TTM
Sales, quarterly000.5170.3010.7530.4670.4950.4061.028
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual5.822103.004103.229103.674130.028193.001277.798
Period202020212022202320242025MRQ
Shares, quarterly119.843130.028155.119156.343158.835193.001222.019277.798277.798
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY
Total Revenue2.402.040.000.000.000.000.00
Cost of Goods Sold Incl. D&A17.3217.057.197.728.268.288.43
Gross Profit-14.93-15.01-7.19-7.72-8.26-8.28-8.43
Selling, General and Administrative Excl. Other95.3692.43107.2192.3377.8974.1957.66
Research and Development66.3168.7088.6076.5563.2661.3454.08
Other Operating Expense0.000.000.000.000.000.000.00
Operating Income-110.29-107.44-114.40-100.05-86.14-82.47-66.09
Interest Expense10.0511.259.286.606.204.352.20
Unusual Expense-23.76-75.2729.1312.70-76.18-59.060.00
Net Income Before Taxes-94.76-40.83-148.70-110.78-11.96-26.48-66.52
Income Taxes0.000.000.000.000.000.000.00
Consolidated Net Income-94.76-40.83-148.70-110.78-11.96-26.48-66.52
Net Income From Continuing Operations-94.76-40.83-148.70-110.78-11.96-26.48-66.52
Net Income-94.76-40.83-148.70-110.78-11.96-26.48-66.52
EPS (Recurring)-0.40-0.59-1.08-0.99-0.63-1.70-11.43
EPS (Basic, Before Extraordinaries)-0.43-0.26-1.26-1.07-0.12-0.66-11.43
EPS (Diluted)-0.43-0.26-1.26-1.07-0.12-0.66-11.43
EBITDA-103.20-100.09-107.21-92.33-77.89-74.19-57.66
Non-Operating Income (Expense)1.822.594.108.574.191.281.77
Other After Tax Adjustments0.000.000.000.000.000.000.00
Stock Option Compensation Expense11.1010.416.146.836.1810.154.69
Price To Sales Ratio60.0274.54-----
Gross Margin-623.02-736.46-----
Operating Margin-4,602.92-5,271.69-----
Net Margin-3,955.05-2,003.58-----
Shares Outstanding277.80193.00130.03103.67103.23103.005.82
Market Capitalization163.90163.90113.49113.49113.49113.49134.55

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue1.030.410.490.470.750.300.520.00
Cost of Goods Sold Incl. D&A2.292.122.0410.872.122.071.981.81
Gross Profit-1.26-1.72-1.54-10.40-1.37-1.77-1.46-1.81
Selling, General and Administrative Excl. Other22.2625.2827.3920.4323.0227.9521.7226.28
Research and Development14.1018.1419.4614.6117.2722.0115.4220.66
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-23.52-27.00-28.93-30.84-24.39-29.73-23.18-28.09
Interest Expense2.372.322.273.092.612.543.002.51
Unusual Expense-9.757.87-13.26-8.62-8.906.22-64.66-8.80
Net Income Before Taxes-15.54-36.80-17.62-24.80-17.51-37.6639.14-20.94
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-15.54-36.80-17.62-24.80-17.51-37.6636.77-20.94
Net Income From Continuing Operations-15.54-36.80-17.62-24.80-17.51-37.6636.77-20.94
Net Income-15.54-36.80-17.62-24.80-17.51-37.6636.77-20.94
EPS (Recurring)-0.08-0.13-0.14-0.17-0.15-0.21-0.06-0.21
EPS (Basic, Before Extraordinaries)-0.06-0.16-0.09-0.13-0.11-0.240.28-0.16
EPS (Diluted)-0.06-0.16-0.09-0.13-0.11-0.240.28-0.16
EBITDA-21.79-25.21-27.14-29.05-22.52-27.87-21.35-26.28
Non-Operating Income (Expense)0.600.390.330.500.590.830.660.85
Other After Tax Adjustments0.000.000.000.000.000.00-2.370.00
Stock Option Compensation Expense2.342.613.172.982.512.432.491.69
Price To Sales Ratio60.0286.1659.5488.03175.34397.14434.53-
Gross Margin-122.91-423.15-311.72-2,227.62-182.20-588.70-282.79-
Operating Margin-2,287.84-6,649.26-5,845.45-6,603.00-3,239.04-9,876.08-4,484.33-
Net Margin-1,511.48-9,064.53-3,559.39-5,311.35-2,325.37-12,510.967,111.22-
Shares Outstanding277.80277.80222.02193.00158.84156.34155.12130.03
Market Capitalization164.37210.43134.70185.37276.37324.20219.38113.49

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY
Cash & Short Term Investments50.6445.0880.59151.88225.5039.93
Short Term Receivables0.440.000.000.030.180.11
Inventories13.590.000.000.000.000.00
Other Current Assets3.122.782.692.303.661.41
Total Current Assets67.8047.8683.28154.21229.3441.45
Net Property, Plant & Equipment47.6939.1544.7050.0957.1965.24
Total Investments and Advances0.2150.210.210.000.000.00
Intangible Assets---0.000.000.00
Other Assets0.670.650.030.000.000.00
Total Assets116.37137.87128.22204.30286.53106.69
Short Term Debt Incl. Current Port. of LT Debt2.433.022.6110.882.034.22
Accounts Payable5.404.496.491.592.092.27
Income Tax Payable---0.000.170.14
Other Current Liabilities10.5412.459.347.116.764.59
Total Current Liabilities18.3719.9518.4419.5811.0511.23
Long Term Debt62.4277.4755.4939.8249.1524.64
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities-----0.14
Other Liabilities32.4793.1140.7427.97104.160.00
Total Liabilities113.26190.54114.6887.37164.3636.02
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.00420.99
Common Equity3.11-52.6713.55116.93122.17-350.32
Total Shareholders Equity3.11-52.6713.55116.93122.1770.67
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity3.11-52.6713.55116.93122.1770.67
Total Liabilities & Stockholders Equity116.37137.87128.22204.30286.53106.69
Book Value Per Share0.02-0.410.131.131.19-60.17
Tangible Book Value Per Share0.02-0.410.131.131.19-60.17
Full-Time Employees1842201831641462
Price to Book Ratio5.241.361.361.361.361.35
Return on Assets-32.12-111.77-66.63-4.88-13.66-
Return on Equity---169.81-10.01-24.61-
Return on Invested Capital-62.31-599.48-160.45-7.63-15.45-69.80
Quick Ratio2.952.404.527.8820.753.69
Current Ratio3.692.404.527.8820.753.69

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY
Net Income-94.76-40.83-148.70-110.78-11.96-26.48-66.52
Depreciation7.097.347.197.728.268.288.43
Other Funds (Non Cash)2.06-48.1643.0823.18-68.45-62.444.89
Funds from Operations-85.62-81.65-98.43-79.88-72.16-80.63-53.20
Extraordinary Item0.000.000.000.000.000.000.00
Changes in Working Capital-2.65-23.390.316.571.03-0.56-2.37
Cash from Operating Activities-88.26-105.04-98.12-73.31-71.13-81.19-55.57
Capital Expenditures-0.32-0.88-1.57-2.28-1.05-0.22-0.32
Net Assets From Acquisitions0.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.05
Purchase or Sale of Investments0.000.000.002.115.89-8.000.00
Purchase of Investments0.000.000.000.00-10.11-8.000.00
Sale Or Maturity of Investments0.000.000.002.1116.000.000.00
Other Uses0.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.00
Cash from Investing Activities-0.32-0.88-1.57-0.174.84-8.22-0.27
Cash Dividends Paid0.000.000.000.000.000.000.00
Change in Capital Stock133.61113.4497.370.570.540.600.30
Repurchase of Common Pref Stock0.000.000.000.000.000.000.00
Sale of Common Pref Stock133.61113.4497.370.570.540.600.30
Proceedsfrom Stock Options133.57113.3895.860.000.000.000.00
Issuance or Reduction of Debt, Net38.1936.3817.665.70-1.9827.931.75
Change in Long Term Debt38.1936.3817.665.70-1.9827.931.75
Issuance of Long Term Debt39.1839.1820.2439.460.0029.663.25
Reduction of Long Term Debt-0.99-2.80-2.58-33.76-1.98-1.73-1.50
Net Financing Active Other Cash Flow-38.18-88.34-0.85-1.760.00238.460.00
Other Financing Activities Uses-38.18-88.34-0.85-1.760.00-3.940.00
Cash from Financing Activities133.6261.49114.184.51-1.45266.982.05
Net Change in Cash45.03-44.4414.49-68.97-67.73177.57-53.78
Free Cash Flow-88.58-105.93-99.69-75.58-72.18-81.41-55.89
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments64.6780.0548.6850.6419.6338.03
Short Term Receivables0.810.330.430.441.080.39
Inventories5.616.999.9213.5918.4211.07
Other Current Assets11.595.424.563.122.222.24
Total Current Assets82.6892.7963.6067.8041.3551.73
Net Property, Plant & Equipment42.6844.4246.0847.6949.2835.63
Total Investments and Advances0.210.210.210.210.2150.21
Intangible Assets0.00-----
Other Assets0.000.670.670.670.671.22
Total Assets125.57138.09110.56116.3791.51138.79
Short Term Debt Incl. Current Port. of LT Debt0.611.522.432.435.745.21
Accounts Payable2.824.165.085.409.576.63
Other Current Liabilities21.339.278.6810.5410.269.25
Total Current Liabilities24.7614.9516.1918.3725.5821.09
Long Term Debt65.8764.6663.4762.4244.8378.45
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities16.8727.2219.2732.4725.8535.20
Total Liabilities107.51106.8398.93113.2696.26134.74
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity18.0631.2611.623.11-4.754.05
Total Shareholders Equity18.0631.2611.623.11-4.754.05
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity18.0631.2611.623.11-4.754.05
Total Liabilities & Stockholders Equity125.57138.09110.56116.3791.51138.79
Book Value Per Share0.070.110.050.02-0.030.03
Tangible Book Value Per Share0.070.110.050.02-0.030.03
Full-Time Employees---184--
Price to Book Ratio9.1014.9037.66-32.1167.138.99
Return on Assets-87.31-69.87-71.47-33.99-38.15-44.06
Return on Equity-1,423.62-547.87-409.47---
Return on Invested Capital-18.51-38.37-23.46-37.85-43.69-45.64
Quick Ratio3.115.743.322.950.901.93
Current Ratio3.346.213.933.691.622.45

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-15.54-36.80-17.62-24.80-17.51-37.66
Depreciation1.731.791.791.791.861.86
Other Funds (Non Cash)-6.8511.67-7.975.20-4.1410.78
Funds from Operations-20.66-23.34-23.80-17.81-19.78-25.02
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital5.691.28-1.30-8.31-4.12-1.40
Cash from Operating Activities-14.97-22.06-25.10-26.12-23.90-26.41
Capital Expenditures0.00-0.10-0.17-0.04-0.05-0.57
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities0.00-0.10-0.17-0.04-0.05-0.57
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.0053.7023.3256.596.203.23
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.0053.7023.3256.596.203.23
Proceedsfrom Stock Options0.0053.6723.3256.586.203.23
Issuance or Reduction of Debt, Net-0.18-0.170.0038.54-0.74-0.73
Change in Long Term Debt-0.18-0.170.0038.54-0.74-0.73
Issuance of Long Term Debt0.000.000.0039.180.000.00
Reduction of Long Term Debt-0.18-0.170.00-0.64-0.74-0.73
Net Financing Active Other Cash Flow-0.230.000.00-37.95-50.05-0.34
Other Financing Activities Uses-0.230.000.00-37.95-50.05-0.34
Cash from Financing Activities-0.4153.5323.3257.17-44.592.17
Net Change in Cash-15.3831.36-1.9631.01-68.54-24.82
Free Cash Flow-14.97-22.16-25.28-26.16-23.95-26.98

Revenue breakdown

Product2025: 1.39M
Product and Service, Other2025: 649.00K
United States2025: 2.04M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3010.93%28.1M256.8M6.46M
2026-10-1511.78%30.3M256.8M6.61M
2026-09-3011.45%29.4M256.8M6.81M
2026-09-1512.37%31.8M257.1M10.25M
2026-08-3111.60%29.8M257.1M10.95M
2026-08-1412.45%31.9M256.4M10.64M
2026-07-3112.65%31.5M248.9M10.40M
2026-07-1512.97%32.3M248.9M10.47M
2026-06-3012.92%31.6M244.5M9.63M
2026-06-1515.01%36.7M244.5M8.01M
2026-05-2919.94%40.1M201.3M7.19M
2026-05-1520.44%41.2M201.3M6.92M
2026-04-3022.14%44.7M201.9M6.83M
2026-04-1523.78%44.8M188.6M6.93M
2026-03-3122.39%42.2M188.6M6.95M
2026-03-1324.81%40.7M164.0M5.31M
2026-02-2723.28%38.2M164.0M5.21M
2026-02-1323.90%39.2M164.0M5.27M
2026-01-3023.69%38.8M164.0M4.88M
2026-01-1522.66%37.2M164.0M4.76M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call0.500.000.450.082.9365142640.723-0.0050.000
call1.000.000.050.053.95671.000.000.292-0.0070.000
call1.500.000.050.005.3930.000.000.245-0.0090.000
call2.000.003.800.036.2931.000.000.225-0.0100.000
put0.500.002.550.000.0000.000.00-0.277-0.0050.000
put1.000.001.450.500.00023.000.00-0.708-0.0070.000
put1.500.003.501.000.0005.000.00-0.755-0.0090.000
put2.000.004.001.437.65710.000.00-0.775-0.0100.000

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-1010-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-108-KCurrent report2026-11-10SEC
2026-10-074Statement of changes in beneficial ownership of securities2026-10-06SEC
2026-10-074Statement of changes in beneficial ownership of securities2026-10-06SEC
2026-09-283Initial statement of beneficial ownership of securities2026-09-22SEC
2026-09-288-KCurrent report2026-09-22SEC
2026-09-283Initial statement of beneficial ownership of securities2026-09-22SEC
2026-09-154Statement of changes in beneficial ownership of securities2026-09-14SEC
2026-08-2525-NSESEC
2026-08-214Statement of changes in beneficial ownership of securities2026-08-20SEC
2026-08-194Statement of changes in beneficial ownership of securities2026-08-17SEC
2026-08-18SCHEDULE 13D/ASEC
2026-08-1210-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-128-KCurrent report2026-08-12SEC
2026-07-318-KCurrent report2026-07-31SEC
2026-07-28SCHEDULE 13G/ASEC
2026-07-13SCHEDULE 13D/ASEC
2026-06-22SCHEDULE 13GSEC
2026-06-15SCHEDULE 13D/ASEC
2026-06-124Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-124Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-124Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-124Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-124Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-124Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-124Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-124Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-124Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-124Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-124Statement of changes in beneficial ownership of securities2026-06-11SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-095.62K100
2026-0824.75K200
2026-070000
2026-060000
2026-0559.84K282.29K2
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
VANGUARD CAPITAL MANAGEMENT LLC3.75%
ANTIPODES PARTNERS Ltd2.97%
Alyeska Investment Group, L.P.2.23%
DAVIDSON KEMPNER CAPITAL MANAGEMENT LP1.85%
BlackRock, Inc.1.79%
GREAT POINT PARTNERS LLC1.39%
UBS Group AG1.08%
GEODE CAPITAL MANAGEMENT, LLC0.96%
AQR CAPITAL MANAGEMENT LLC0.96%
MILLENNIUM MANAGEMENT LLC0.71%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND2.86%
VANGUARD EXTENDED MARKET INDEX FUND0.79%
Fidelity Small Cap Index Fund0.71%
iShares Biotechnology ETF0.53%
VANGUARD RUSSELL 2000 INDEX FUND0.38%
Fidelity Extended Market Index Fund0.35%
Schwab U.S. Small-Cap ETF0.31%
Modern Capital Tactical Income Fund0.22%
VANGUARD HEALTH CARE INDEX FUND0.21%
Schwab Small-Cap Index Fund0.17%

OakChart. HUMA. Cached 15 minutes.